Introduction
The Massachusetts Male Aging Study noted that erectile dysfunction (ED) is a common disorder in men between 40 and 70 years of age with a prevalence of 52%. 1 Penile erection and detumescence are regulated by corporeal smooth muscle relaxation and contraction. ED mainly results from the inadequate relaxation of the penile corpora cavernosal smooth muscle during sexual stimulation. 2 Penile erection has been shown to be mainly mediated by nitric oxide (NO). 3 NO is released from penile non-adrenergic, non-cholinergic nerve endings and endothelial cells of corpus cavernosum and penile blood vessels and additionally from the smooth muscle. [4] [5] [6] NO diffuses into the smooth muscle cell, and activates soluble guanylyl cyclase, which in turn gives rise to the production of cyclic guanosine monophosphate (cGMP). NO-induced increase in intracellular cGMP levels results in the relaxation of the cavernous smooth muscle by reducing intracellular Ca 2 þ . The above-mentioned pathway appears to be of major importance to modulate erectile function. Factors disrupting this pathway may impair the relaxation of corporeal smooth muscle and may lead to ED. 7 Sildenafil citrate is the first phosphodiesterase type 5 (PDE-5) inhibitor approved by Food and Drug Administration (1998). PDE-5 inhibition causes an elevation in intracellular cGMP level as cGMP is degraded intracellularly by PDE. 8 Therefore, PDE-5 inhibition augments the normal erectile response. Sildenafil has been shown to be beneficial in men with ED owing to organic, psychogenic and mixed etiological factors. Goldstein et al. 9 have reported an overall beneficial effect of sildenafil in 70% of patients compared with that of placebo (20-30%). As sildenafil acts through the inhibition of intracellular cGMP degradation, it is obvious that the physiological production of this PDE substrate in response to NO is an essential step in sildenafil action. Therefore, any impairment in this process might result in irresponsiveness to sildenafil treatment. However, to the best of our knowledge, there has not been any satisfactory explanation of sildenafil irresponsiveness in the literature.
NO is synthesized as a by-product during L-citrulline production from L-arginine, a reaction catalyzed by the enzyme NO synthase (NOS). 8 Three isoforms of NOS, namely neuronal (nNOS, NOS 1), inducible (iNOS, NOS 2) and endothelial (eNOS, NOS 3) NOSs have been determined. 10 All three isoforms of NOS have been shown to play a role within the penile tissues. eNOS is mainly expressed in endothelial cells and is involved in several important cardiovascular functions. Therefore, regulation of the expression of NOS isoforms including any polymorphism of the gene encoding for NOS enzyme might be of clinical importance.
Several previous studies have supported this suggestion by pointing out the association of intron 4 variable number of tandem repeats (VNTR), E298A and IVF 23 þ 10 G/T polymorphisms of eNOS gene with diabetes-related and cardiovascular disorders.
11,12 Thus, we aimed to investigate the possible association of eNOS gene intron 4 VNTR, E298A and IVF 23 þ 10 G/T polymorphisms in particular, with the responsiveness to sildenafil treatment in patients with ED. We hypothesized that ED patients with eNOS gene polymorphisms respond less to sildenafil.
Materials and methods
Ninety-six male patients suffering from ED and 167 healthy individuals representing normal population in our country were included in the study. Patients were evaluated by a detailed medical history, physical examination followed by laboratory tests, including serum glucose, lipid profile, testosterone, prolactine and combined intracavernous injection, and stimulation test. Penile Doppler ultrasonography was performed when indicated. Following this initial evaluation, the etiology (vasculogenic, neurologic, endocrinologic, mixed and psychogenic) and contributing risk factors (atherosclerosis, diabetes mellitus, hyperlipidemia, medications, smoking and cardiovascular comorbidities) were defined. Patient profile with regard to the risk factors is given in Table 1 . Sexual function before and after treatment were determined by the five-item version of International Index of Erectile Function (IIEF-5). The degree of the severity of ED of the patients was classified into five categories according to their IIEF-5 scores. Success with treatment was defined according to IIEF-5 categories as 4 (mild ED) and 5 (no ED). Out of 96 patients, sildenafil was given to 67 men with no contraindication for sildenafil use. The dosage ranged from 25 to a maximum 100 mg. Those who did not respond to 100 mg were regarded as non-responders (Tables 2-4) .
Genotyping
All of the participant patients were requested to sign the written informed consent form regarding the protocol of the present study, including the blood sample collection for DNA analysis. The Ethics Abbreviation: ED, erectile dysfunction. Association between intron 4 VNTR, E298A and IVF 23 þ 10 G/T polymorphisms L Peskircioglu et al Committee of our faculty approved the study protocol. Genomic DNA was prepared from leukocyte pellets by sodium dodecyl sulfate lysis, ammonium acetate extraction and ethanol precipitation. 13 The primers and polymerase chain reaction (PCR) conditions were performed as described previously. 14 
Gel analysis and genotyping
The PCR products of b and a alleles were identified by the presence of 420 and 393 bp bands on 2% agarose gel electrophoresis, respectively, for ecNOS intron 4 VNTR genotypes. The E298A polymorphism of ecNOS gene was detected by digesting a 152 bp amplified fragment with BanII. In the case of a G-to-T substitution at position 894 in exon 7 of the ecNOS gene, a BanII restriction site is lost. The G allele consisted of 56 and 96 bp.
A 676 bp PCR product was cut with HindII for ecNOS intron 23 G10-T polymorphism. The amplified DNA was then digested by HindII into fragments (577 and 99 bp). In the case of a G-to-T substitution at position 10 of intron 23 of the ecNOS gene, an additional HindII restriction site was produced and the amplified fragments were digested into smaller fragments (374, 203 and 99 bp).
Statistical analysis
The statistical comparison between the frequencies of ecNOS gene polymorphisms among groups (the patient group, the sildenafil received group and the control group) was carried out by w 2 test.
Results
The Association between intron 4 VNTR, E298A and IVF 23 þ 10 G/T polymorphisms L Peskircioglu et al non-responders. However, this difference was statistically insignificant.
Discussion
NO, a potent relaxant of peripheral vascular smooth muscle with an action mediated by cGMP, has been shown to be the major mediator of penile erection. [3] [4] [5] In the penis, NO is synthesized mainly from the penile nerve endings by the reaction catalyzed by NOS1. Nevertheless, additional sources for endogenous NO production have been shown, 6 that is, in addition to the above-mentioned major biosynthesis process, NO can also be produced in the penile endothelium and corpora cavernosal smooth muscle by the enzymes NOS3 and NOS2. When diffused into the neighboring smooth muscle cells, NO activates soluble guanylyl cyclase to produce cGMP, which finally mediates a reduction in intracellular Ca 2 þ level leading to the relaxation of penile corpora cavernosal smooth muscle.
The inability of the cavernosal smooth muscle to undergo complete relaxation results in ED, which is manifested in aging and in several cardiovascular and metabolic diseases, such as diabetes mellitus, 15 myocardial infarction and atherosclerosis. 16, 17 It was shown previously that hypertension impairs NO availability owing to the production of cyclooxygenase-derived vasoconstrictor substances and reduced endothelin B receptor-mediated NO activation. 16 Experimental studies verify impaired NOS activity in diabetes and hyperlipidemia.
A bulk of evidence from animal models and from clinical trials has reported the beneficial effect of NO level augmentation in ED. 18, 19 Two major therapeutic strategies may serve to increase penile NO levels in ED, that is, the use of NO donor agents and the inhibitors of cGMP degradation. cGMP is hydrolyzed to GMP by the catalyzing action of the highly specific cGMP-binding enzyme, PDE-5, which is specifically inhibited by sildenafil. Sildenafil, therefore, enhances the effects of NO on corporeal arterial and on sinusoidal smooth muscle by inhibiting the catabolism of cGMP, unless the cGMP biosynthetic process is impaired. Thus, any step in this biosynthetic process, including the NOproducing reaction by eNOS, plays an essential role in the therapeutic effect of sildenafil.
To our knowledge, there is only one study demonstrating the relation between ED and molecular basis of sildenafil response. Eisenhardt et al. 12 have reported that individuals having D allele of angiotensin-converting enzyme gene respond to sildenafil less. However, the authors could not show a relation between sildenafil response and NOS3 E298A polymorphism.
The findings of the present study may indicate a possible relationship between T allele carriers of ecln23 gene and ED. However, we could not determine an association between sildenafil response and ecNOS IVS 23 þ 10G/T and E298A polymorphisms.
eNOS exon 7 genotype distribution in men with ED was similar to that in healthy population.
In this study, we found that patients with 'a' allele of ecNOS intron 4 VNTR show a better response to sildenafil than do 'b' allele carriers. We suggest that 'a' allele carriers are more prone to erections supported by sildenafil. On the other hand, 'b' allele carriers are expected to develop diabetes or cardiovascular morbidities that will damage their vascular endothelium and prevent their response to sildenafil in the future.
In conclusion, we suggest that ecNOS intron 4 VNTR polymorphism may be one of the determining factors for sildenafil response in ED and that it might be used as a predictive indicator while developing a treatment strategy for this widely seen disease.
